Lexeo Therapeutics, Inc. $LXEO Stake Lifted by Privium Fund Management B.V.

Privium Fund Management B.V. raised its stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 11.3% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 178,356 shares of the company’s stock after buying an additional 18,158 shares during the quarter. Privium Fund Management B.V. owned approximately 0.54% of Lexeo Therapeutics worth $753,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Affinity Asset Advisors LLC acquired a new stake in shares of Lexeo Therapeutics in the 1st quarter worth about $5,139,000. Palumbo Wealth Management LLC bought a new position in Lexeo Therapeutics in the 2nd quarter worth about $226,000. Ground Swell Capital LLC bought a new stake in shares of Lexeo Therapeutics during the first quarter valued at approximately $80,000. Nuveen LLC acquired a new position in shares of Lexeo Therapeutics during the first quarter worth approximately $125,000. Finally, CWM LLC boosted its position in shares of Lexeo Therapeutics by 150.3% during the second quarter. CWM LLC now owns 10,351 shares of the company’s stock worth $42,000 after buying an additional 6,216 shares during the period. Institutional investors and hedge funds own 60.67% of the company’s stock.

Lexeo Therapeutics Stock Down 3.8%

NASDAQ:LXEO opened at $9.22 on Tuesday. Lexeo Therapeutics, Inc. has a 52-week low of $1.45 and a 52-week high of $11.72. The firm has a market cap of $497.88 million, a P/E ratio of -2.83 and a beta of 1.66. The business’s 50-day moving average price is $6.00 and its 200 day moving average price is $4.46.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.04. Sell-side analysts expect that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on LXEO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexeo Therapeutics in a research note on Wednesday, October 8th. Oppenheimer started coverage on shares of Lexeo Therapeutics in a research note on Thursday, July 31st. They set an “outperform” rating and a $20.00 price objective on the stock. Leerink Partners increased their target price on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Chardan Capital raised their target price on shares of Lexeo Therapeutics from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Finally, HC Wainwright upped their price target on shares of Lexeo Therapeutics from $9.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.86.

Insider Transactions at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 13,133 shares of the company’s stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $8.94, for a total value of $117,409.02. Following the completion of the sale, the chief executive officer owned 242,118 shares in the company, valued at approximately $2,164,534.92. This represents a 5.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Adler sold 3,382 shares of the firm’s stock in a transaction on Friday, October 17th. The stock was sold at an average price of $8.94, for a total value of $30,235.08. Following the completion of the sale, the insider directly owned 73,261 shares of the company’s stock, valued at approximately $654,953.34. This trade represents a 4.41% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 29,091 shares of company stock valued at $232,007 over the last three months. Company insiders own 5.30% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.